A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 699 participants.

Also called NCT07187115

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 699 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07187115
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Hong Kong SAR China, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07187115. Randomized; no masking; primary purpose treatment. Start 2025-11-07 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Acronym
OPTIMIZE
Condition
Atrial Fibrillation (AF)
Condition
Persistant Atrial Fibrillation
Intervention (Device)
FARAPOINT Pulsed Field Ablation System
Intervention (Device)
OptiMap System (non-ablative)
Intervention (Device)
FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07187115
Content hash
595784abf519748726a11777fdc26e03c87a245f8b0480b50cbb44672373fb7c